TNF-α regulates the effects of irradiation in the mouse bone marrow microenvironment

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Cachaço, Ana Sofia ^a   Carvalho, Tânia ^a   Santos, Ana Cristina ^b   Igreja, Cátia ^a,e   Fragoso, Rita ^a,f   Rio, Catarina Osó ^a   Ferreira, Manuela ^a,g   Serpa, Jacinta ^a   Correia, Sofia ^d   Pinto do Ó, Perpétua ^d   Dias, Sérgio ^a,c  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^d INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^e MAX PLANCK INSTITUTE   (Germany)

^f STANFORD UNIVERSITY   (United States)

^g IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE; NEUTRALIZING ANTIBODY; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; LEUKOCYTE COUNT; MACROCYTIC ANEMIA; MEGAKARYOCYTE; MICROENVIRONMENT; MICROSATELLITE MARKER; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RADIATION DOSE; THROMBOCYTOPENIA; ZYMOGRAPHY; ANIMAL; BLOOD; BLOOD CELL COUNT; BONE MARROW; C57BL MOUSE; CELL LINE; DRUG EFFECT; ENZYME ACTIVATION; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; LEUKOCYTE; MALE; METABOLISM; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIATION EXPOSURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULARIZATION; WESTERN BLOTTING;

MUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; APOPTOSIS; BLOOD CELL COUNT; BLOTTING, WESTERN; BONE MARROW; BONE MARROW CELLS; CELL LINE; ENZYME ACTIVATION; FLOW CYTOMETRY; LEUKOCYTES; MALE; MATRIX METALLOPROTEINASES; MEGAKARYOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77749280454     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008980     Document Type: Article

References (42)

1. Baud V, Karin M (2001) Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11: 372-377.
2. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539-345.
3. Lejeune FJ, Rüegg C (2006) Recombinant human tumor necrosis factor: an efficient agent for cancer treatment. Bull Cancer 93(8): E90-100.
4. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, et al. (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5: 828-831.
5. Scott KA, Arnott CH, Robinson SC, Moore RJ, Thompson RG, et al. (2004) TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratocyte migration? Oncogene 23: 6954-6966.
6. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, et al. (2004) Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 25(8): 1543-9.
7. Yang WL, Godwin AK, Xu XX (2004) Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: molecular basis linking ovulation and cancer risk. Cancer Res 64(4): 1534-40.
8. Redondo-Muñoz J, Escobar-Díaz E, Samaniego R, Terol MJ, García-Marco JA, et al. (2006) MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 108(9): 3143-51.
9. Rosselli F, Sancean J, Gluckman E, et al. (1994) Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. In vitro and in vivo spontaneous overproduction of tumor necrosis factor α Blood 83(5): 1216-1225.
10. Dufour C, Corcione A, Svahn J, Haupt R, Poggi V, et al. (2003) TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood 102(6): 2053-9.
11. Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, et al. (2003) Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol 71(5): 396-8. Erratum in: Eur J Haematol. (2004) 72(4):306.
12. Hara T, Ando K, Tsurumi H, Moriwaki H (2004) Excessive production of tumor necrosis factor-alpha by bone marrow T lymphocytes is essential in causing bone marrow failure in patients with aplastic anemia. Eur J Haematol 73(1): 10-6.
13. Kerbauy DB, Deeg HJ (2007) Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndromes. Exp Hematol 35(11): 1739-46.
14. Lv L, Kerzic P, Lin G, Schnatter AR, Bao L, et al. (2007) The TNF-alpha 238A polymorphism is associated with susceptibility to persistent bone marrow dysplasia following chronic exposure to benzene. Leuk Res 31(11): 1479-85.
15. Boula A, Voulgarelis M, Giannouli S, Katrinakis G, Psyllaki M, et al. (2006) Effect of cA2 anti.tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res 12: 3099-3108.
16. Deeg HJ, Gotlib J, Beckham C, Dugan K, Holmberg L, et al. (2002) Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 16(2): 162-164.
17. Maciejewski JP, Risitano AM, Sloand EM, Wisch L, Geller N, et al. (2002) Br J Haematol 117(1): 119-26. Erratum in: Br J Haematol (2002) 117(4):1002. Ristiano Antonio M [corrected to Risitano Antonio M].
18. De Roos AJ, Deeg HJ, Davis S (2007) A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. Cancer Causes Control 18(10): 1199-1208.
19. Malcovati L, Nimer SD (2008) Myelodysplastic syndromes: Diagnosis and Staging. Cancer Control 15(4 Supplement): 4-13.
20. Haran-Ghera N, Peled A, Krautghamer R, Resnitzky P (1992) Initiation and promotion in radiation-induced myeloid leukemia. Leukemia 6(7): 689-95.
21. Padmanabhan A, Baker JA, Zirpoli G, Sait SN, Ford LA, et al. (2008) Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family members. Leuk Res 32(12): 1820-3.
22. Zhang Y, Harada A, Bluethmann H, Wang JB, Nakao S, et al. (1995) Tumor necrosis factor (TNF) is a physiologic regulator of hematopoietic progenitor cells: increase of early hematopoietic progenitor cells in TNF receptor p55-deficient mice in vivo and potent inhibition of progenitor cell proliferation by TNF alpha in vitro. Blood 86(8): 2930-7.
23. Rebel VI, Hartnett S, Hill GR, Lazo-Kallanian SB, Ferrara JL, et al. (1999) Essential role for the p55 tumor necrosis factor receptor in regulating hematopoiesis at a stem cell level. J Exp Med 190(10): 1493-504.
24. Drutskaya MS, Ortiz M, Liepinsh DJ, Kuprash DV, Nedospasov SA, et al. (2005) Inhibitory effects of tumor necrosis factor on hematopoiesis seen in vitro are translated to increased numbers of both committed and multipotent progenitors in TNF-deficient mice. Exp Hematol 33(11): 1348-56.
25. Rübe CE, Wilfert F, Uthe D, Schmid KW, Knoop R, et al. (2002) Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. Radiother Oncol 64(2): 177-87.
26. Zhang M, Qian J, Xing X, Kong FM, Zhao L, et al. (2008) Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung. Clin Cancer Res 14(6): 1868-76.
27. Daigle JL, Hong JH, Chiang CS, McBride WH (2001) The role of tumor necrosis factor signaling pathways in the response of murine brain to irradiation. Cancer Res 61(24): 8859-65.
28. Dy LC, Pei Y, Travers JB (1999) Augmentation of ultraviolet B radiation-induced tumor necrosis factor production by the epidermal platelet-activating factor receptor. J Biol Chem 274(38): 26917-21.
29. Müller K, Meineke V (2007) Radiation-induced alterations in cytokine production by skin cells. Exp Hematol 35(4 Suppl 1): 96-104.
30. Tolle DV, Seed TM, Fritz TE, Lombard LS, Poole CM, et al. (1979) Acute monocytic leukemia in an irradiated Beagle. Vet Pathol 16(2): 243-54.
31. Seed TM, Chubb GT, Tolle DV (1981) Sequential changes in bone marrow architecture during continuous low dose gamma irradiation. Scan Electron Microsc 4: 61-72.
32. Sato H, Seiki M (1993) Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8: 395-405.
33. Wielockx B, Lannoy K, Shapiro SD (2001) Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med 7: 1202-1208.
34. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, et al. (2002) Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 31:109(5): 625-37.35.
35. Natoli G, Costanzo A, Guido F, Moretti F, Bernardo A, et al. (1998) Nuclear factor kB-independent cytoprotective pathways originating at tumor necrosis factor receptor-associated factor 2. J Biol Chem 273(47): 31262-72.36.
36. Barkett M, Gilmore TD (1999) Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18(49): 6910-24.
37. Priestley GV, Scott LM, Ulyanova T, Papayannopoulou T (2006) Lack of a4 integrin expression in stem cells restricts competitive function and self-renewal activity. Blood 107: 2959-2967.
38. Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH (2007) Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 129(6): 1081-95. (A).
39. Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, et al. (2007) A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 129(6): 1097-110. (B)
40. Leone G, Pagano L, Ben-Yehuda D, Voso MT (2007) Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92(10): 1389-98.
41. Reza S, Shetty V, Dar S, Qawi H, Raza A (1998) Tumor necrosis factor-α levels decrease with anticytokine therapy in patients with myelodysplastic syndromes. J Interferon Cytokine Res 18(10): 871-7.
42. Raza A, Qawi H, Lisak L, Andric T, Dar S, et al. (2000) Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 95(5): 1580-7.